1403P EGFR-mutation testing and TKI treatment patterns in locally advanced or metastatic NSCLC in Norway: A nationwide cohort study

Abstract

Since 2013, the national Norwegian guidelines recommend that all non-squamous non-small cell lung carcinomas (NSCLC) are tested for epidermal growth-factor receptor mutations (EGFRm+). For EGFRm+ advanced NSCLC patients, 1st line palliative treatment with tyrosine kinase inhibitors (TKI) is recommended. This is the first nation-wide study describing real-world EGFR testing and subsequent TKI-treatment patterns in Norway.